RxDoctor Payments Data

Usama Gabr, MD

Pain Medicine · Columbia, SCNPI 1124089453

Payments from drug & device makers

What this record shows

This record is dominated by gifts: $6,190 of the $8,205 with a category attached, or 75.4%. AbbVie accounts for 76.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $6,803 and has fallen 99.7% since, to $19 in 2025.

$8,205in general payments, 2019–2025

Across 93 payments — averaging $88.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$244
  • Merz Pharmaceuticals, LLC$185
  • Aesculap, Inc.$165
  • Daiichi Sankyo Inc.$164
  • AstraZeneca$158
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$1,85123%
  • Gifts$6,19075%
  • Other$1652%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,205 in reported general payments places this provider in the 75th percentile of 92 pain medicine providers in South Carolina.

See all pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$138,506
Medicare patients
92
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide48$116,289
Xtampza ErOxycodone Myristate87$53,091
SavellaMilnacipran Hcl60$29,092
MovantikNaloxegol Oxalate71$28,284
OxycontinOxycodone Hcl30$25,236
Nucynta ErTapentadol Hcl18$22,055
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,112$20,988
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen793$18,582
Oxymorphone Hcl ErOxymorphone Hcl22$14,506
Morphine Sulfate ErMorphine Sulfate364$11,043
Gabapentin1,030$10,379
Baclofen898$8,241
Lubiprostone100$7,866
LinzessLinaclotide11$5,736
Diclofenac Sodium207$4,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$244$116,28948 claims
AbbVieSavella, Linzess$6,282$34,82871 claims
Redhill Biopharma Inc.Movantik$15$28,28471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 pain medicine providers in South Carolina.

Other pain medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →